Updated safety analysis


Ongoing safety evaluations from ocrelizumab clinical trials and associated open-label extension periods, as well as selected post-marketing safety data.

COVID-19 in ocrelizumab-treated people with multiple sclerosis
Hughes R, Whitley L, Fitovski K, et al. Mult Scler Relat Discord. Published online ahead of print December 30, 2020. doi: https://doi.org/10.1016/j.msard.2020.102725
COVID-19 in Persons With Multiple Sclerosis Treated With Ocrelizumab – A Pharmacovigilance Case Series.
Hughes R, Pedotti R, Koendgen H. Mult Scler Relat Disord. 2020;42:102192.
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis
Hauser SL, Kappos L, Montalban X, et al. Presented at MSVirtual2020, the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting; 11-13 September 2020.
Download PDF (698kb)
Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study
Bar-Or A, Calkwood JC, Chognot C, et al. Neurology. 2020;95:e1999-e2008.
Cases Reported as Progressive Multifocal Leukoencephalopathy in Ocrelizumab-Treated Patients With Multiple Sclerosis
Clifford DB, Gass A, Richert N, et al. Presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, Sweden; 11-13 September 2019.
Download PDF (1099kb)

Prescribing information

Indications vary in different countries. The local prescribing information from your country is the primary source of information on the known and potential risks associated with ocrelizumab.